Enlonstobart
Phase 3Small molecule
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Enlonstobart is one of 193 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.
5
Indications
8
Total Trials
8
Active Trials
192
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Avastin
RochePhase 3
Adstiladrin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
Enlonstobart
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
YL202
MMediLink Therapeutics (Suzhou) Co., Ltd.
Phase 3
Remeron
OOrganon and Co
Preclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Gastric Cancer2 trials
Non-Small Cell Lung Cancer2 trials
Head and Neck Squamous Cell Carcinoma1 trial
Cervical Cancer1 trial
A Single-Arm Exploratory Study of Enlansibumab Sequentially Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
Not yet recruiting·—·Phase 2·NCT06981858·34 enrolled
Liver Cancer1 trial
Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer
Not yet recruiting·CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1/2·NCT07282509·116 enrolled
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1/2·NCT07282509·116 enrolled1 more indication
Rectal Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Enlonstobart. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details